Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) CAO Theodore Alan Huizenga sold 2,163 shares of the company’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $40.80, for a total transaction of $88,250.40. Following the transaction, the chief accounting officer now owns 23,614 shares in the company, valued at $963,451.20. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Theodore Alan Huizenga also recently made the following trade(s):
- On Friday, September 1st, Theodore Alan Huizenga sold 970 shares of Ultragenyx Pharmaceutical stock. The stock was sold at an average price of $37.15, for a total transaction of $36,035.50.
Ultragenyx Pharmaceutical Trading Up 0.7 %
Shares of NASDAQ:RARE traded up $0.30 during trading on Monday, hitting $41.45. 555,784 shares of the company were exchanged, compared to its average volume of 604,789. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $33.36 and a fifty-two week high of $54.98. The stock has a market cap of $2.96 billion, a price-to-earnings ratio of -3.96 and a beta of 0.87. The firm has a fifty day moving average price of $40.34 and a two-hundred day moving average price of $43.20.
Wall Street Analysts Forecast Growth
RARE has been the subject of a number of analyst reports. Evercore ISI raised shares of Ultragenyx Pharmaceutical from an “in-line” rating to an “outperform” rating and lifted their target price for the stock from $60.00 to $80.00 in a report on Tuesday, June 6th. Morgan Stanley reaffirmed an “overweight” rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, August 4th. Citigroup increased their target price on Ultragenyx Pharmaceutical from $130.00 to $133.00 in a research note on Wednesday, June 7th. Wedbush decreased their target price on Ultragenyx Pharmaceutical from $49.00 to $47.00 in a research report on Friday, August 4th. Finally, StockNews.com initiated coverage on shares of Ultragenyx Pharmaceutical in a research report on Thursday, August 17th. They issued a “hold” rating on the stock. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $81.21.
Hedge Funds Weigh In On Ultragenyx Pharmaceutical
A number of institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. increased its holdings in shares of Ultragenyx Pharmaceutical by 33.6% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 951 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 239 shares during the last quarter. Quadrant Capital Group LLC raised its position in shares of Ultragenyx Pharmaceutical by 111.4% in the fourth quarter. Quadrant Capital Group LLC now owns 924 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 487 shares during the period. Signaturefd LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 42.6% during the 2nd quarter. Signaturefd LLC now owns 1,021 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 305 shares during the last quarter. Van ECK Associates Corp bought a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth about $53,000. Finally, American International Group Inc. grew its stake in Ultragenyx Pharmaceutical by 36.3% in the 2nd quarter. American International Group Inc. now owns 1,257 shares of the biopharmaceutical company’s stock valued at $58,000 after buying an additional 335 shares during the last quarter. Institutional investors and hedge funds own 96.37% of the company’s stock.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
- Five stocks we like better than Ultragenyx Pharmaceutical
- What is the NASDAQ Stock Exchange?
- An Electrifying New Upgrade for Tesla Leads the Market Higher
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Oil Jumps, 2 Plastic Stocks About To Become Value Plays
- Industrial Products Stocks Investing
- The Top 5 Analysts Calls in September
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.